Exelixis (EXEL) gains on test results

Exelixis, Inc. EXEL shares rose 41% to $5.51 after the company reported positive top-line results from METEOR, Phase 3 pivotal trial of Cabozantinib vs. Everolimus in patients with metastatic renal cell carcinoma. Share volume totaled 34.2 million, dwarfing an all-day average of 3.2 million